Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Parsabiv

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

- PMLiVE

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

- PMLiVE

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Room for manoeuvre after initial rejection

- PMLiVE

NICE appraisal fees to be introduced despite opposition

Concessions made for small companies

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

- PMLiVE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

But it is only available via the CDF for now

- PMLiVE

Medical cannabis now available on prescription, for some

But it can’t be prescribed for chronic pain

- PMLiVE

Amgen CEO says Aimovig is “one of most successful launches”

Contrasts with cholesterol drug Repatha, its price slahed 60% to lift take-up

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links